Health Care Reform's Impact Reflected In Pharma's Q1 Results
Executive Summary
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
You may also be interested in...
Amgen Quarterly Report: Profits Up, HCR Fears Down
Amgen says health care reform will trim its sails, but it's not much compared to the blow it took from the ESA safety problems.
Abbott Lowers 2010 Guidance Due To U.S. Health Care Reform; Q1 Sales Rise 14.6%
Abbott adjusted its previous 2010 earnings per share guidance by $0.07 to range from $4.13 to $4.18.
J&J Braces For Health Care Reform Hit, But Can "Accommodate" Impact
J&J's 2010 sales will be $400 million to $500 million lower due to health care reform, although J&J didn't significantly lower 2010 earnings as a result.